正电子发射体层成像（PET）扫描

预约门诊
打印

科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心协力确保高品质治疗与成功康复。

有相关专长的科室

研究此手术的领域

行此手术的医生

编辑搜索过滤条件
close

缩小搜索范围

  1. 未找到姓氏以该字母开头的医生 A
  2. 查找姓氏以该字母开头的医生 B
  3. 查找姓氏以该字母开头的医生 C
  4. 查找姓氏以该字母开头的医生 D
  5. 未找到姓氏以该字母开头的医生 E
  6. 未找到姓氏以该字母开头的医生 F
  7. 未找到姓氏以该字母开头的医生 G
  8. 查找姓氏以该字母开头的医生 H
  9. 未找到姓氏以该字母开头的医生 I
  10. 查找姓氏以该字母开头的医生 J
  11. 未找到姓氏以该字母开头的医生 K
  12. 查找姓氏以该字母开头的医生 L
  13. 查找姓氏以该字母开头的医生 M
  14. 查找姓氏以该字母开头的医生 N
  15. 未找到姓氏以该字母开头的医生 O
  16. 主动 查找姓氏以该字母开头的医生 P
  17. 未找到姓氏以该字母开头的医生 Q
  18. 未找到姓氏以该字母开头的医生 R
  19. 未找到姓氏以该字母开头的医生 S
  20. 未找到姓氏以该字母开头的医生 T
  21. 未找到姓氏以该字母开头的医生 U
  22. 未找到姓氏以该字母开头的医生 V
  23. 未找到姓氏以该字母开头的医生 W
  24. 未找到姓氏以该字母开头的医生 X
  25. 未找到姓氏以该字母开头的医生 Y
  26. 未找到姓氏以该字母开头的医生 Z
重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

姓氏首字母: P

  1. Anshuman J. Panda, Ph.D.

    Anshuman J. Panda, Ph.D.

    1. Medical Physicist
    1. Phoenix, AZ
    擅长领域：

    Radiation therapy, MRI, Positron emission tomography scan

  2. Robert A. Pooley, Ph.D.

    Robert A. Pooley, Ph.D.

    1. Medical Physicist
    1. Jacksonville, FL
    擅长领域：

    MRI, Positron emission tomography scan

研究

目前，接受过 PET 扫描和其他成像技术培训的放射科医生和科学家们在研究如何充分利用 PET 扫描来预测和诊断范围广泛的各种疾病和医疗状况。2012 年，美国食品药品管理局批准妙佑医疗国际生产和使用胆碱 C-11 注射剂。这是一种在 PET 扫描过程中用于帮助检测复发性前列腺癌部位的显像剂。妙佑医疗国际是北美第一家获准生产胆碱 C-11 的机构。

文献著述

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗作者在 PET 扫描领域的著述目录。

Research Profiles

来自妙佑医疗国际员工

在 Mayo Clinic 治疗

申请预约
关于在 Mayo Clinic 治疗
July 09, 2026
打印
  1. PET/CT. RadiologyInfo. https://www.radiologyinfo.org/en/info/PET. Accessed March 18, 2026.
  2. Fact sheet: What is PET? Society of Nuclear Medicine and Molecular Imaging. https://snmmi.org/Patients/Patients/Fact-Sheets/What-is-PET.aspx. Accessed March 18, 2026.
  3. Unterrainer M, et al. Recent advances of PET imaging in clinical radiation oncology. Radiation Oncology. 2020; doi:10.1186/s13014-020-01519-1.
  4. Adam A, et al., eds. Functional and molecular imaging for personalized medicine in oncology. In: Grainger and Allison's Diagnostic Radiology. 7th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed March 26, 2026.
  5. ACR-SPR practice parameters for performing FDG-PET/CT in oncology. American College of Radiology. https://gravitas.acr.org/PPTS. Accessed March 18, 2026.
  6. Cervical cancer. RadiologyInfo. https://www.radiologyinfo.org/en/info/cervicalcancer. Accessed March 27, 2026.
  7. Singnurkar A, et al. Head-to-head comparison of the diagnostic performance of FDG PET/CT and FDG PET/MRI in patients with cancer: A systematic review and meta-analysis. American Journal of Roentgenology. 2024; doi:10.2214/AJR.24.31519.
  8. Choline C‑11 (approval letter). New Drug Application 203155. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203155. Accessed March 30, 2026.
  9. Ferri FF. Diagnostic imaging. In: Ferri's Best Test: A Practical Guide to Clinical Laboratory Medicine and Diagnostic Imaging. 5th ed. Elsevier; 2023. https://www.clinicalkey.com. Accessed March 26, 2026.
  10. Gelardi F, et al. Match point: Nuclear medicine imaging for recurrent thyroid cancer in TENIS syndrome-systematic review and meta-analysis. Journal of Clinical Medicine. 2024; doi:10.3390/jcm13185362.
  11. Datta D, et al. Diagnostic performance of F-18 FDG PET/CT in differentiating autoimmune pancreatitis from pancreatic cancer: A systemic review and meta-analysis. Annals of Nuclear Medicine. 2024; doi:10.1007/s12149-024-01934-4.
  12. Verger A, et al. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: Version 1.0. European Journal of Nuclear Medicine and Molecular Imaging. 2025; doi:10.1007/s00259-024-07038-5.
  13. Carlson DM, et al. Baseline characteristics and use of pretherapeutic 18 F-fluorodeoxyglucose-PET for pancreatic cancer. Journal of the American College of Surgeons. 2024; doi:10.1097/XCS.0000000000001059.
  14. Evangelista L, et al. The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: A systematic literature review. Annals of Nuclear Medicine. 2021; doi:10.1007/s12149-021-01629-0.
  15. PSMA PET scan for prostate cancer. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/psma-pet-scan/about/pac-20582225. Accessed March 27, 2026.
  16. Fendler WP, et al. PSMA PET/CT: Joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. European Journal of Nuclear Medicine and Molecular Imaging. 2023; doi:10.1007/s00259-022-06089-w.
  17. Radiation dose. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/safety-xray. Accessed March 27, 2026.
  18. Voter AF, et al. A practical guide to the pearls and pitfalls of PSMA PET imaging. Seminars in Nuclear Medicine. 2023; doi:10.1053/j.semnuclmed.2023.11.001.
  19. Samim A, et al. SUV normalisation and reference tissue selection for [18F]mFBG PET-CT in paediatric and adult patients. European Journal of Nuclear Medicine and Molecular Imaging. 2025; doi:10.1007/s00259-025-07242-x.
  20. Choline C-11 PET scan. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/choline-c-11-pet-scan/about/pac-20384628. Accessed March 30, 2026.
  21. FDA approves 11C-choline for PET in prostate cancer. Journal of Nuclear Medicine. 2012; 53:11N.

相关

Mayo Clinic 新闻

产品与服务

正电子发射体层成像（PET）扫描